|
David D. Pendergast Ph.D. was appointed our Executive Chairman in February 2008 and serves as Chairman of our Board of Directors a position he has held since November 2007 after having served as a member of our board of directors since November 2006. Dr. Pendergast was formerly the President Human Genetics Therapies at Shire Pharmaceuticals plc and has more than 30 years of experience in pharmaceutical development and corporate operations. In his position at Shire Dr. Pendergast was responsible for the discovery development manufacture and commercialization of protein therapeutics. He was also a member of Shire’s Management Committee which reports to the board of the directors and is responsible for strategic direction corporate governance and operational performance. Prior to joining Shire Dr. Pendergast served as Chief Executive Officer of Transkaryotic Therapies Inc. (acquired by Shire in 2005) where he managed the company during the acquisition; Chief Operating Officer where he oversaw operational functions ranging from discovery to commercialization of protein therapies; and Executive Vice President Technical Operations where he was responsible for manufacturing process development quality and engineering. Dr. Pendergast was also previously Vice President of Product Development and Quality at Biogen Inc. (now Biogen Idec) and held senior positions at Fisons Ltd. Pharmaceutical Division and at The Upjohn Company (now part of Pfizer). He holds a Ph.D. in Pharmacy and M.S. in Chemistry from University of Wisconsin and a B.A. in Chemistry/Math from Western Michigan University.
| 